Publications & Posters
Scholarly publications
Immuno-Oncology
SRK-181
November 2022
Poster Hall
SRK-181, a latent TGFβ1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors
Platform
November 2022
Antibodies
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
Spinal Muscular Atrophy
Apitegromab
October 2022
International Scientific Congress on SMA
Apitegromab in SMA: Efficacy, Safety and PK/PD Assessments in 24 Months of TOPAZ
Spinal Muscular Atrophy
Apitegromab
October 2022
WMS Hybrid Congress
Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study (P.102)
Immuno-Oncology
SRK-181
September 2022
12th Annual World Clinical Biomarkers & CDx Summit
Development of a Comprehensive Biomarker Strategy for the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
Immuno-Oncology
SRK-181
September 2022
American College of Clinical Pharmacology Annual Meeting
